Medtronic's (MDT) planned separation of its diabetes business may create shareholder value in the long term, Needham said Friday in a note.
The separation probably won't "immediately unlock significant value," though "we think that the two companies are likely to see better results as separate entities" in the longer term, Needham said.
Medtronic's margins will increase with the separation and Symplicity, Affera and Hugo will have a bigger impact on the company's growth rate, the report said.
The diabetes segment will be able to decide whether to reinvest free cash flow back into its own business "and should become more nimble and responsive to customer needs and market trends," the report said.
The proposed split is expected to be completed in 18 months, the report said.
Needham has a hold rating on Medtronic stock.
Price: 87.30, Change: +0.30, Percent Change: +0.34
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.